Clinical Trials: Page 26
-
Permission granted by Relay Therapeutics
Relay impresses with early study data for targeted cancer drug
Updated data released ahead of the ESMO medical conference suggest Relay’s medicine could be more effective than others like it in treating a type of bile duct cancer.
By Ned Pagliarulo • Sept. 8, 2022 -
Alnylam details anticipated results from heart disease drug trial
Fuller data from the APOLLO-B study confirm the success reported by Alnylam last month, but won’t end debate on the magnitude of the drug’s benefit.
By Ben Fidler • Sept. 8, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Porpeller via Getty Images
Iveric readies eye drug for FDA following study success
The drug slowed eye lesion growth in people with geographic atrophy, positioning it to become the second treatment for the disease to reach the FDA.
By Ben Fidler • Sept. 6, 2022 -
Courtesy of Sarepta
Sarepta to restart Duchenne drug study after FDA lifts hold
The biotech will expand patient monitoring in response to a previously reported serious adverse reaction that had led the FDA in June to suspend testing.
By Ned Pagliarulo • Sept. 6, 2022 -
Amgen says KRAS drug beat chemo in lung cancer study
But the company offered no details on the closely watched trial, which is meant to confirm the effectiveness of Lumakras in non-small cell lung cancer.
By Ned Pagliarulo • Aug. 31, 2022 -
SciePro via Getty Images
Jounce’s latest setback dampens outlook for another cancer immunotherapy target
The biotech's drug prospect vopratelimab has become the latest member of a group of medicines targeting a molecule called ICOS to fall short of expectations in clinical testing.
By Jonathan Gardner • Aug. 30, 2022 -
AstraZeneca, matching Lilly, reports positive heart failure data for diabetes pill
The new data position AstraZeneca to significantly expand use of Farxiga in heart failure and compete with Lilly and Boehringer Ingelheim’s rival drug Jardiance.
By Jonathan Gardner • Aug. 29, 2022 -
libre de droit via Getty Images
Bristol Myers, Bayer study results seed doubt about an emerging group of blood thinners
Though the companies plan to move their medicines into late-stage testing, they each missed their main Phase 2 goals, raising questions about the prospects of so-called Factor XI inhibitors.
By Christopher Newman • Aug. 29, 2022 -
24K-Production via Getty Images
Sponsored by Worldwide Clinical TrialsPsychedelic clinical trials: What sponsors should know when designing new protocols
With regulators and lawmakers seemingly on board, sponsors have more opportunities than ever to pursue clinical research in this high-velocity area.
Aug. 29, 2022 -
Spencer Platt via Getty Images
Pfizer follows GSK with positive Phase 3 results for RSV vaccine
In a pre-planned interim data analysis, Pfizer said its shot was strongly protective against severe disease and plans to submit the results to regulators this fall.
By Delilah Alvarado • Aug. 25, 2022 -
Dr_Microbe via Getty Images
Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
Researchers reported signs of nerve damage in patients treated with the drug branaplam, which is among the most advanced candidates now in testing.
By Jonathan Gardner • Aug. 24, 2022 -
Selvanegra via Getty Images
Biotech Erasca taps MD Anderson to help advance cancer drug work
The five-year partnership is one of many inked between the cancer center and drugmakers like Erasca, which is targeting a cellular pathway linked to many types of tumors.
By Christopher Newman • Aug. 23, 2022 -
Sarah Silbiger via Getty Images
Pharvaris studies of rare disease drug put on hold by FDA
The agency suspended two trials of Pharvaris’ experimental treatment for hereditary angioedema after reviewing nonclinical data, the biotech said.
By Ned Pagliarulo • Aug. 22, 2022 -
CSL says drug for rare swelling disorder succeeds in late-stage study
The company plans to soon seek approval of a once-monthly preventive drug for hereditary angioedema, a disease other drugmakers are targeting with gene editing and RNA medicines.
By Kristin Jensen • Aug. 18, 2022 -
Jose Luis Calvo Martin & Jose Enrique Garcia-Maurino Muzquiz via Getty Images
Blueprint drug succeeds in rare disease study important to its market prospects
Trial results position the company to seek approval for indolent systemic mastocytosis, which executives have painted as a “multibillion dollar” market opportunity. Even so, shares fell by double digits in trading Wednesday.
By Ben Fidler • Updated Aug. 17, 2022 -
Elizabeth Regan/BioPharma Dive
Ventyx touts early data for potential rival to Bristol Myers psoriasis drug
The biotech plans to start Phase 2 studies for a drug it believes may more effectively hit its target than Bristol Myers’ deucravacitinib, a skin disease treatment regulators could approve next month.
By Jonathan Gardner • Aug. 16, 2022 -
Novartis bid to repurpose rare disease drug for cancer falls short in third trial
A study testing Novartis’ canakinumab as an adjuvant lung cancer treatment missed its main goal, closing off an opportunity for an expanded approval.
By Ned Pagliarulo • Aug. 15, 2022 -
Courtesy of Bristol Myers Squibb
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
Abecma, which 2Seventy bio helps develop and sell, is currently approved for patients who have tried at least four other medicines for the blood cancer.
By Ned Pagliarulo • Aug. 10, 2022 -
Erik Karits via Getty Images
Pfizer, Valneva take next step with Lyme disease shot, starting large trial
The experimental vaccine is the most advanced candidate for the tick-borne disease and, if successful, would be the first to reach the market since withdrawal of GSK’s Lymerix.
By Delilah Alvarado • Aug. 9, 2022 -
SciePro via Getty Images
Fresh off Enhertu success, AstraZeneca and Daiichi claim progress for next cancer drug
A treatment that AstraZeneca acquired for up to $6 billion in 2020 is showing early promise as a combination agent in lung cancer, where it’s being tested alongside Merck & Co.’s Keytruda.
By Ben Fidler • Aug. 9, 2022 -
Retrieved from National Cancer Institute on September 27, 2019
Amgen data on KRAS cancer drug disappoints, opening door for rival Mirati
Highly anticipated trial results for Lumakras combinations with immunotherapy fell short of expectations, showing significant liver toxicity that limited dosing.
By Ned Pagliarulo • Aug. 8, 2022 -
Courtesy of Eli Lilly
Lilly takes long view on Alzheimer’s drug as FDA starts expedited review
The pharma said Thursday the FDA had accepted its application for donanemab, starting a six-month evaluation for accelerated approval.
By Ned Pagliarulo • Aug. 5, 2022 -
Jolygon via Getty Images
Alnylam drug succeeds in key heart disease study, boosting company
The success of Alnylam's treatment in a trial known as APOLLO-B could pave the way for the biotech to reach consistent profitability, should the FDA sign off on an approval application.
By Ben Fidler • Aug. 3, 2022 -
Hero Images via Getty Images
Sponsored by Janssen PharmaceuticalsThe promise of oral therapies for cytokine inhibition
The science behind new oral therapies for cytokine inhibition and why they could be transformational for patients.
By David Lee, Global Therapeutic Area Head, Immunology • Aug. 1, 2022 -
Alnylam reveals longer wait for anticipated drug trial results
Important data from the APOLLO study of the biotech's drug Onpattro are due before the end of August, Alnylam said Thursday.
By Ned Pagliarulo • July 28, 2022
Previous
